Key facts
- It has raised $720K; the latest was Seed Round ($10.0M) in Mar 2026.
- Notable investors include Academic Innovations Holding, Baruch S. Blumberg Institute, Mark Petty, Robert Morano, Startup Bucks — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Merlin Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Merlin Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Merlin Biotech
Developer of cancer immune modulators designed to treat adult and pediatric cancers. The company offers mRNA-encoded therapeutics delivered directly to tumors targeting immune pathways, enabling healthcare providers to improve treatment precision and enhance patient outcomes.
- Sector
- Healthcare
- HQ
- Doylestown, PA, United States
- Founded
- 2022
- Employees
- 4
- Website
- merlinbiotech.com/
- Ownership
- Privately Held (backing)
Merlin Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Merlin Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Merlin Biotech in its N-PORT filings yet. We sweep new filings monthly.